Studying Dexamethasone and Prednisone Sensitivity in Samples From Younger Patients With High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia

B-precursor Acute Lymphoblastic Leukemia (ALL): Studying the Mechanisms Behind Dexamethasone and Prednisone Sensitivity in High-Risk Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01553162

Enrollment

Registered

2012-03-14

Start date

2012-04-30

Completion date

Unknown

Last updated

2016-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Keywords

B-cell childhood acute lymphoblastic leukemia, untreated childhood acute lymphoblastic leukemia

Brief summary

RATIONALE: Studying samples of blood, tissue, or bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial is studying dexamethasone and prednisone sensitivity in samples from younger patients with high-risk B-cell precursor acute lymphoblastic leukemia.

Detailed description

OBJECTIVES: * Identify differences in the effect of dexamethasone (Dex) and prednisone (Pred) on glucocorticoid receptor (GR) occupancy and gene expression in high-risk (HR) B-cell precursor (BCP)-acute lymphoblastic leukemia (ALL) samples from patients aged 1-9. * Identify differences in gene expression and GR occupancy of response elements in HR BCP-ALL patients \> 10 years old in response to both Dex and Pred. OUTLINE: Archived samples are analyzed for gene expression analysis and genomic location of glucocorticoid receptor by ChIP sequencing (ChiPseq) and RNA sequencing. Data of gene expression and ChiPseq data sets are compared by luciferase reporter assay.

Interventions

GENETICDNA analysis

GENETICRNA analysis

GENETICgene expression analysis

OTHERlaboratory biomarker analysis

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 21 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Patients diagnosed with high-risk B-cell precursor acute lymphoblastic leukemia * Samples from patients treated and not treated with Dex and Pred PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Genes that are required for efficient apoptosis	—
Differentially expressed genes from both HR BCP-ALL patients aged 1-9 and patients over 10 years old	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026